LLY News and Press, Eli Lilly and Company From 04/06/24

2024-04-06 08:30:00 ET The battle for leadership in the anti-obesity drug market is heating up. Eli Lilly (NYSE: LLY) and Novo Nordisk are the two undisputed frontrunners, but many other drugmakers are looking to challenge the status quo. Novo Nordisk's Wegovy, first approved in...

2024-04-05 17:58:39 ET More on Eli Lilly Eli Lilly: Three Threats To Its Huge Rally Why Eli Lilly And Rival Novo Nordisk Won't Be Troubled By Viking's Latest Weight Loss Data Eli Lilly: Diabetes And Weight Management Treatments Are The Winning Tickets Zepboun...

2024-04-05 11:47:11 ET Summary BlackRock Health Sciences Trust is a diversified closed-end fund that focuses on the healthcare sector, offering a 6.35% dividend yield. BME currently trades at a historical discount to NAV of nearly -8%. The fund presents an attractive opportuni...

2024-04-04 13:30:10 ET Summary Walgreens is a 2,500lb great white in the global healthcare system, but the stock is a minnow. The U.S. Pharmacy business is structurally broken, but the reimbursement model is set for a major change and Walgreens hired the right man for the job. ...

2024-04-04 13:15:40 ET More on Inspire Medical Systems Inspire Medical Systems: Strong Q4 Results But Growth Might Be Slowing Inspire Medical: A Good Night Sleep Inspire Medical Systems, Inc. (INSP) Q4 2023 Earnings Call Transcript KeyBanc picks Inspire, Inte...

2024-04-04 04:55:00 ET Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) have seen their revenue soar in recent times thanks to their weight loss drugs. The companies sell products that target key hormones involved in the regulation of blood sugar levels and appetite, and t...

2024-04-03 12:05:29 ET Eli Lilly’s ( NYSE: LLY ) weight-loss drug Zepbound (tirzepatide) will remain in short supply through April-end amid increased demand, the U.S. Food and Drug Administration (FDA) confirmed on Wednesday.... Read the full article on Seeking Alp...

2024-04-03 11:57:45 ET Summary Enrollment paused in the Verve Therapeutics' phase 1b heart-1 study, using VERVE-101 for the treatment of patients with heterozygous familial hypercholesterolemia after a Grade 3 adverse event. Despite VERVE-101 setback, the ability to move forward w...

2024-04-03 09:30:29 ET Summary Just like Cisco Systems 24 years ago, Nvidia Corporation seems on its way to overtake Microsoft Corporation as the largest company on the planet. However, that might not take for long, with as much as -90% downside afterward. Investors need to be awa...

2024-04-03 07:01:03 ET More on Novo Nordisk Shaping The Future Of Obesity Treatment: GLP-1 Agonists At The Forefront Novo Nordisk: My 'Hold' Thesis For 2024 - The Premium Must Be Justified Novo Nordisk, A Very Healthy Pharma Stalwart CVS, Elevance Health to c...